AdAlta's CEO and Managing Director, Tim Oldham, has been selected to give an oral presentation at ISCT ANZ 2026 describing AdAlta's "East to West" cellular immunotherapy strategy as a new model for commercialising breakthrough therapies for solid cancers.

“Being chosen for an oral presentation is independent validation that our ‘East to West’ model is genuinely novel and important. Connecting Asia’s remarkable cell therapy innovation with Australia’s world-class manufacturing and regulatory ecosystem is a credible, capital-efficient way to bring groundbreaking immunotherapies to cancer patients who currently have few options. We are proud to share this story with the region’s leading scientists, clinicians and developers.”